Archive | Clinical Trials

BGB324 (bemcentinib)

BGB324 (bemcentinib), from BerGenBio, is being developed as a treatment for triple-negative breast cancer, non-small cell lung cancer (NSCLC), acute myeloid leukemia, myelodysplastic syndrome, and metastatic melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

IMCgp100 Highly Effective for Advanced Uveal Melanoma

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% (95% CI, 46%-88%) for patients with heavily pretreated, advanced uveal melanoma, representing a promising new option on the horizon for a disease with few effective options, according to findings presented at the 2018 ARVO Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Advanced Melanoma Patients Seen to Respond to CMP-001, Keytruda Combo in Ongoing Study

Intratumoral injection of CMP-001 in combination with Keytruda (pembrolizumab) worked to reduce tumor burden in advanced melanoma patients whose disease failed to respond, or progressed, when treated with PD-1 inhibitors, data from an ongoing Phase 1 trial show.

Read the full story

Posted in Melanoma In The News, Clinical Trials

PFS Rises with BRAF-MEK Combo in Melanoma

Patients with advanced melanoma lived twice as long without disease progression when they received combination targeted therapy instead of a single agent, a randomized trial showed.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories